Document is current
Any future updates will be listed below
-
Authors
Fu, Dong-Jing
Zhang, Qiaoyi
Shi, Ling
Borentain, Stephane
Guo, Shien
Mathews, Maju
Anjo, Joana
Nash, Abigail I.
O’Hara, Marguerite
Canuso, Carla M.
-
Funding
Funding for this research was provided by:
Janssen Research and Development
- License Information
-
More Information
Article History
Received: 22 June 2022
Accepted: 10 July 2023
First Online: 11 August 2023
Declarations
:
: Over 60 Institutional Review Boards and Independent Ethics Committees approved the study protocol and amendments. The full list can be found in Additional File as well as in the supplementary materials of the primary publications [, ]. The study was conducted in accordance with ethical principles that have their origin in the Declaration of Helsinki, consistent with Good Clinical Practices and applicable regulatory requirements. All patients provided written informed consent before participation in the study.
: Not applicable.
: Dong-Jing Fu, Qiaoyi Zhang, Joana Anjo, Marguerite O’Hara, and Carla Canuso are employees of Janssen Research & Development, LLC and may hold Johnson & Johnson company stocks or stock options. Stephane Borentain, Abigail Nash, and Maju Mathews were employees of Janssen Research & Development, LLC at the time of study and manuscript preparation and may hold Johnson & Johnson company stocks or stock options; Abigail Nash is currently employed by Neurocrine Biosciences Inc.; Maju Mathews is currently employed by Perception Neuroscience. Ling Shi and Shien Guo are employees of Evidera-PPD and received research funding support from Janssen Research & Development, LLC.
